Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues.
Fair value with imperfect balance sheet.
Share Price & News
How has Nexeon MedSystems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NXNN has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NXNN underperformed the US Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: NXNN underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Nexeon MedSystems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Nexeon MedSystems undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NXNN ($0.75) is trading below our estimate of fair value ($3.17)
Significantly Below Fair Value: NXNN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NXNN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: NXNN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NXNN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NXNN is good value based on its PB Ratio (0.2x) compared to the US Medical Equipment industry average (4.1x).
How is Nexeon MedSystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nexeon MedSystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Nexeon MedSystems is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Nexeon MedSystems's filings and announcements here.
- Explore growth companies in the Healthcare industry.
How has Nexeon MedSystems performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NXNN is currently unprofitable.
Growing Profit Margin: NXNN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NXNN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NXNN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXNN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).
Return on Equity
High ROE: NXNN has a negative Return on Equity (-18.1%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Nexeon MedSystems's financial position?
Financial Position Analysis
Short Term Liabilities: NXNN's short term assets ($5.2M) do not cover its short term liabilities ($7.1M).
Long Term Liabilities: NXNN's short term assets ($5.2M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: NXNN's debt to equity ratio (36.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if NXNN's debt to equity ratio has reduced over the past 5 years.
Inventory Level: NXNN has a high level of physical assets or inventory.
Debt Coverage by Assets: NXNN's debt is covered by short term assets (assets are 1.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if NXNN has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NXNN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Nexeon MedSystems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NXNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NXNN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NXNN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NXNN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NXNN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Will Rosellini (39yo)
Mr. William Rosellini, also known as Will, JD, MBA, serves as Principal at Growth Stack, Inc. He has been the Chief Executive Officer at Nexeon MedSystems, Inc. since December 7, 2015 and serves as its Cha ...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD521.92K).
Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.6%.
Nexeon MedSystems Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Nexeon MedSystems Inc.
- Ticker: NXNN
- Exchange: OTCPK
- Founded: 2015
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.527m
- Shares outstanding: 2.04m
- Website: https://www.nexeonmed.com
Number of Employees
- Nexeon MedSystems Inc.
- 1910 Pacific Avenue
- Suite 20000
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NXNN||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Aug 2017|
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson’s disease in the United States, as well as for Parkinson’s disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 03:48|
|End of Day Share Price||2020/02/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.